Member Info for moonparty

Agree with LD being the intellectual / scientific powerhouse and I am sure it's a vocation for her, and not at all about financial gain. I wouldn't be surprised to see the scib or modi platforms sold (for billions!) once phase 2 shows the potential. Then big pharma can do the 'admin' of phase 3 and getting to market whilst LD works on the next thing she had an idea about out.

Thanks for replys all. I can see this would have to be a frequent treatment, as per kidney dialysis, but it may be useful in certain situations - e.g. if a patient has a handful of treatable tumours, it could be used to minimise the risk of further metastesis whilst treatment is ongoing.
However, Angle clearly have the best commercial use of the technology in sight and I think this comes a long way down the list of commercial viability and usefulness.
Have a good weekend all.

Thanks for the reply Malachi, but could it prevent the metastasis happening in the first place?

Saw the proactive presentation, which was excellent, and I am very confident with my small holding here.
Whilst watching, it occured to me that the technology could be used as a kind of 'cancer dialysis' to cleanse the blood of cancer cells.
I'm sure I am being completely naive, and this is not possible, practical or economical!
Would appreciate comments from more knowledgeable folk on the (probably blindingly obvious) reasons why this isn't a 'thing'.

Crackin - 18 posts over last 30 days, 8 of which have been deleted. All negative about Scancell. None contributing any new information or insight.
Why??

How many more hits can Starship Scancell take before the cloaking device is down?

Looking at maybe taking a position here, hope somebody can help me - have i got my facts straight?
- market cap about £6.5M
- LCCM seems to be the main short-term prize and should be highly profitable once up and running, which could be within the next 12 months.
- Cobre seems to be the cash cow that should fund everything else and cover salaries / keep the lights pn
- Redmoor looks good but early stage, maybe 2 - 3 years before production, if it happens?
- Bit of a debacle went on with Cobre sales, with the BoD seemingly duped, and a lot of revenue lost because of it. Market is understandably not impressed.

If anyone can shed any light on:
- predicted numbers from Cobre and LCCM?
- anything positive about BoD - previous successes etc..

Many thanks to any who reply :)

She has invested £7,185.695
When you paste this into google you get this:
https://www.ncbi.nlm.nih.gov/gene/718569

Is it a clue? :) :) :)

I seem to have got just under 30% of the excess I applied for in my II account.
The spare money has not been credited yet, but I understand that may take a day or 2.

Probably means existing large holders (e.g. Vulpes) applied for their full entitlement - more votes of confidence :)

After the 10am shareholders meeting?
We should hear about open offer then... possibly. Or tomorrow morning at latest

I have been following Lloyds as I sold my entire holding at the start of covid at a loss.
Down another 8% today on very poor results, and about 50% since the start of the year - this kind of volatility in blue chips was extremely rare before covid. Similar story for the likes of Capita, Shell etc..

If you're going to be in the market right now I don't think traditionally safe stocks are really safe anymore. And dividends are cancelled, substantially reduced or at the least subject to doubt.
If you don't have the near-certainty of a dividend and retention of capital, what is the benefit of 'safe' stocks over potential high-capital-growth stocks like Scancell?

Yep KonarA is right - the buy/sell indicator is just a simple 'is the price higher or lower than the mid price'.
That's all that can be done, as the exchange only publishes a price.
For SETS stocks, buyers and sellers are matched, so each trade is effectively a buy and a sell, so it tells you is whether a buyer or seller took the available trade.
For MM controlled stocks (like SCLP) it tells you whether an investor sold to the MM or bought from the MM.
In both cases it is still only an indication based on mid-price.

With delayed trades, the 'mid' price used is usually the price at the time the trade is reported, not the time the trade took place, so the buy/sell indicator can be completely off.

Apologies for man-splaining . My partner accuses me of this a lot :)

Have to say, I am very comfortable holding my Scancell shares right now - the funding is sorted, the trial runway is clear, news on so many fronts is imminent.
I find it hard to imagine there will be another fund raising before some transformational commercial action takes place.

I have cashed in many of my pension and isa funds since Covid hit - too risky holding too many 'safe' blue chips at the moment in my opinion. I will sit on the cash until the damage / changes to the world economy are clearer - I suspect there will be greater disruption than the market is predicting but WTFDIK?
My only substantial individual holding is Scancell and a 'risky' Australian gold miner, which seem less risky than the 'safe' blue chips at the moment!

Very happy to use some of my cash to keep adding, via the OO and excess. The progress made, though disappointing in commercial terms, gives me confidence that the science is spot on.
The stakeholders, both financial (Vulpes, Redmile) and institutional (BionTech, CRUK and others) just increase my confidence, as do the various peer-reviewed publications in scientific journals.

Like many here, I have a substantial holding which will be life changing if Scancell delivers even 10% of it's potential.

Serious bargains! - I was looking at taking the kids to to the Italian lakes next month - you can fly to Milan for £19 return in August. Combine that with an airbnb villa.

So, reasons for delay? Here's a few for starters:

- Expecting deal news imminently, closed period, wouldn't be able to say anything useful.
- Expecting covid non-dilutive funding news imminently, closed period, wouldn't be able to say anything useful.
- Simply too busy with all the trials work
- CH / LD booked a last minute holiday - there are some seriously cheap deals around :)
- Advanced negotiations for a sale of the entire business for £billions ...

From RNS 24th April:
"Initial research is underway and Scancell anticipates initiating a Phase 1 clinical trial ("COVIDITY") in Q1 2021, subject to funding."
Phase 1 = human trial for tolerance and efficacy.

I also remember someone posting that LD said Phase 1 could be sooner, funds allowing.

Lochinvar,
I thought preclinical was underway already and human trials Q1 2021 (or earlier) ?

Interactive Investor (lI) have informed me the details will be in all eligible accounts later today or by tomorrow morning :)

ha ha :)